D. Archer

发表

Vaginal cytokines do not correlate with postmenopausal vulvovaginal symptoms

N. Bersinger, A. Thurman, Z. Kollmann, 2015, Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology.

Serum steroids remain within the same normal postmenopausal values during 12-month intravaginal 0.50% DHEA

F. Labrie, C. Martel, D. Archer, 2015, Hormone molecular biology and clinical investigation.

Ethinyl estradiol and 17β-estradiol in combined oral contraceptives: pharmacokinetics, pharmacodynamics and risk assessment.

D. Archer, F. Stanczyk, David F Archer, 2013, Contraception.

Tibolone histology of the endometrium and breast endpoints study: design of the trial and endometrial histology at baseline in postmenopausal women.

A. Ferenczy, W. den Hollander, D. Archer, 2007, Fertility and sterility.

Menopausal hot flushes and night sweats: where are we now?

A. Maclennan, M. Hickey, A. Pines, 2011, Climacteric : the journal of the International Menopause Society.

Assessment of compliance with a weekly contraceptive patch (Ortho Evra/Evra) among North American women.

A. Fisher, D. Archer, A. Bigrigg, 2002, Fertility and sterility.

The impact of improved compliance with a weekly contraceptive transdermal system (Ortho Evra) on contraceptive efficacy.

A. Fisher, D. Archer, G. Creasy, 2004, Contraception.

Metabolism of free and sulfoconjugated DHEA in brain tissue in vivo and in vitro.

D. Archer, P. Knapstein, A. David, 1968, Steroids.

Use of Contraceptives for Older Women

D. Archer, 2007 .

Updated 2013 International Menopause Society recommendations on menopausal hormone therapy and preventive strategies for midlife health

R. Langer, V. Henderson, S. Davis, 2013, Climacteric : the journal of the International Menopause Society.

Effects of progesterone, levonorgestrel and medroxyprogesterone acetate on apoptosis in human endometrial endothelial cells.

D. Archer, Shumei Zhao, C. Choksuchat, 2009, Contraception.

Endometrial bleeding during hormone therapy: the effect of progestogens.

D. Archer, 2007, Maturitas.

Intravaginal dehydroepiandrosterone (prasterone), a highly efficient treatment of dyspareunia

C. Labrie, F. Labrie, C. Martel, 2011, Climacteric : the journal of the International Menopause Society.

Intravaginal dehydroepiandrosterone (Prasterone), a physiological and highly efficient treatment of vaginal atrophy

C. Labrie, F. Labrie, C. Martel, 2009, Menopause.

Long-term safety of drospirenone-estradiol for hormone therapy: a randomized, double-blind, multicenter trial

R. Kempson, P. Bitterman, V. Hanes, 2005, Menopause.

Role of the nonhuman primate for research related to women's health.

D. Archer, 2004, ILAR journal.

A randomized comparison of continuous combined transdermal delivery of estradiol-norethindrone acetate and estradiol alone for menopause

D. Archer, D. Tipping, M. Dain, 1999 .

A review of the endometrial histologic effects of progestins and progesterone receptor modulators in reproductive age women.

D. Archer, Alistair R W Williams, A. Dinh, 2015, Contraception.

Endometrial effects of tibolone.

A. Ferenczy, W. den Hollander, D. Archer, 2007, The Journal of clinical endocrinology and metabolism.

Cardiovascular, cerebrovascular, and hepatic safety of desvenlafaxine for 1 year in women with vasomotor symptoms associated with menopause

D. Archer, J. Pinkerton, C. Guico-Pabia, 2012, Menopause.

CHAPTER SIX – Primate Lactogenic Hormones and Functions

D. Archer, B. Larson, J. Josimovich, 1978 .

Current concepts of prolacting physiology in normal and abnormal conditions.

D. Archer, E. Wallach, 1977, Fertility and sterility.

Drospirenone, a progestin with added value for hypertensive postmenopausal women.

D. Archer, 2007, Menopause.

Commentary on "menopausal hormone treatment in postmenopausal women: risks and benefits".

D. Archer, 2014, Southern medical journal.

Tissue-Selective Estrogen Complexes

D. Archer, 2010, Drugs & aging.

Medical decisions regarding hormone therapy for menopausal women are significantly influenced by the media

D. Archer, 2007, Pharmacoepidemiology and drug safety.

Cervicovaginal colposcopic lesions associated with 5 nonoxynol-9 vaginal spermicide formulations.

L. Meyn, D. Archer, E. Raymond, 2008, American journal of obstetrics and gynecology.

Ospemifene's effects on lipids and coagulation factors: a post hoc analysis of phase 2 and 3 clinical trial data

D. Archer, Wei Jiang, S. Cort, 2017, Menopause.

Endometrial morphology in asymptomatic postmenopausal women.

M. Kafrissen, D. Archer, G. Creasy, 1991, American journal of obstetrics and gynecology.

Ospemifene for the treatment of menopausal vaginal dryness, a symptom of the genitourinary syndrome of menopause

I. Goldstein, J. Simon, D. Archer, 2019, Expert review of endocrinology & metabolism.

Estrogen and progestogen effect on venous thromboembolism in menopausal women

E. Oger, D. Archer, David F. Archer, 2012, Climacteric : the journal of the International Menopause Society.

Efficacy and tolerability of local estrogen therapy for urogenital atrophy

D. Archer, 2010, Menopause.

Drospirenone and estradiol: a new option for the postmenopausal woman

D. Archer, 2007, Climacteric : the journal of the International Menopause Society.

Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause

F. Labrie, C. Martel, D. Archer, 2015, Menopause.

Science of intracrinology in postmenopausal women

F. Labrie, C. Martel, D. Archer, 2017, Menopause.

Serum steroid concentrations remain within normal postmenopausal values in women receiving daily 6.5mg intravaginal prasterone for 12weeks

F. Labrie, C. Martel, D. Archer, 2016, The Journal of Steroid Biochemistry and Molecular Biology.

Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause

F. Labrie, C. Martel, D. Archer, 2016, Menopause.

A randomized, double-blind, placebo-controlled study of the lowest effective dose of drospirenone with 17&bgr;-estradiol for moderate to severe vasomotor symptoms in postmenopausal women

C. Gerlinger, D. Archer, T. Schmelter, 2014, Menopause.

Effects of bazedoxifene/conjugated estrogens on the endometrium and bone: a randomized trial.

R. Lindsay, A. Chines, J. Harvey, 2014, The Journal of clinical endocrinology and metabolism.

Differential effects of menopausal therapies on the endometrium

B. Komm, H. Taylor, D. Archer, 2014, Menopause.

Ultra-low-dose continuous combined estradiol and norethisterone acetate: improved bleeding profile in postmenopausal women

D. Archer, D. Sturdee, V. Rakov, 2008, Climacteric : the journal of the International Menopause Society.

Ultra-low-dose estradiol and norethisterone acetate: effective menopausal symptom relief

R. Gut, N. Panay, D. Archer, 2007, Climacteric : the journal of the International Menopause Society.

Neoplasia of the female reproductive tract

D. Archer, 2004, Endocrine.

Body mass index does not affect the efficacy or bleeding profile during use of an ultra-low-dose combined oral contraceptive.

S. Nakajima, D. Archer, J. Pappadakis, 2016, Contraception.

Gestodene: a review of its pharmacology, potency and tolerability in combined contraceptive preparations.

D. Archer, F. Stanczyk, 2014, Contraception.

Toward early safety alert endpoints: exploring biomarkers suggestive of microbicide failure.

G. Doncel, D. Weiner, R. Fichorova, 2013, AIDS research and human retroviruses.

Menstrual-cycle-related symptoms: a review of the rationale for continuous use of oral contraceptives.

D. Archer, 2006, Contraception.

Predictors of response for elagolix with add-back therapy in women with heavy menstrual bleeding associated with uterine fibroids

K. Barnhart, E. Puscheck, A. Al-Hendy, 2020, American journal of obstetrics and gynecology.

Evaluation of a continuous regimen of levonorgestrel/ethinyl estradiol for contraception and control of menstrual symptoms

D. Archer, J. Jensen, 2008, Expert opinion on pharmacotherapy.

Uterine endometrial peristalsis--a transvaginal ultrasound study.

J S Abramowicz, J. Abramowicz, D. Archer, 1990, Fertility and sterility.

Peritoneal fluid: its relevance to the development of endometriosis.

D. Archer, J. Ramey, 1993, Fertility and sterility.

Interleukin-6 and tumor necrosis factor-alpha concentrations in the intrauterine cavity of postmenopausal women using an intrauterine delivery system releasing progesterone. A possible mechanism of action of the intrauterine device.

D. Archer, K. R. DeSoto, J. Baker, 1999, Contraception.

The effect of progesterone on the accumulation of leukocytes in the human endometrium.

D. Archer, J. Hsiu, S. S. Booker, 1994, American journal of obstetrics and gynecology.

Effects of chronic nocturnal opiate antagonism on the menstrual cycle.

D. Archer, R. Brzyski, A. Viniegra, 1992, American journal of obstetrics and gynecology.

Prolactin response to thyrotropin-releasing hormone in women with infertility and/or randomly elevated serum prolactin levels.

D. Archer, 1987, Fertility and sterility.

Metabolism of estradiol-6,7-3H by the human fallopian tube. I. Effects of prostaglandin F2alpha in vitro.

D. Archer, R. L. Fronduti, 1974, Fertility and sterility.

Estrogen formation in vitro by fetal liver, fetal adrenal gland, and placenta of early human pregnancy.

D. Archer, C. Wu, G. Flickinger, 1970, American journal of obstetrics and gynecology.

Treatment of Endometriosis-Associated Pain with Elagolix, an Oral GnRH Antagonist: Results from a Phase 2, Randomized Controlled Study

L. Giudice, N. Watts, H. Taylor, 2015, The New England journal of medicine.

Effects of mifepristone on vascular endothelial growth factor and thrombospondin-1 mRNA in Ishikawa cells: implication for the endometrial effects of mifepristone.

D. Archer, S. Mirkin, 2004, Contraception.

Profile of estetrol, a promising native estrogen for oral contraception and the relief of climacteric symptoms of menopause

J. Foidart, R. Houtman, F. Lenfant, 2022, Expert review of clinical pharmacology.

The assessment of bleeding patterns in postmenopausal women during continuous combined hormone replacement therapy: a review of methodology and recommendations for reporting of the data

D. Archer, J. Pickar, 2002, Climacteric : the journal of the International Menopause Society.

Tibolone: Selective Tissue Estrogen Activity Regulator Utilization in Postmenopausal Women

J. Gallagher, D. Archer, 2007 .

Effects of ospemifene on the female reproductive and urinary tracts: translation from preclinical models into clinical evidence

H. Taylor, G. Constantine, D. Archer, 2015, Menopause.

Endometrial Effects of Bazedoxifene Acetate, a Novel Selective Estrogen Receptor Modulator, in Postmenopausal Women

E. Baracat, G. Constantine, D. Archer, 2005, Obstetrics and gynecology.

Effect of raloxifene, 17beta-estradiol, and progesterone on mRNA for vascular endothelial growth factor isoforms 121 and 165 and thrombospondin-1 in Ishikawa cells.

D. Archer, S. Mirkin, Francisco J Navarro, 2003, Fertility and sterility.

Bleeding Patterns in Postmenopausal Women Taking Continuous Combined or Sequential Regimens of Conjugated Estrogens With Medroxyprogesterone Acetate

D. Archer, J. Pickar, F. Bottiglioni, 1994, Obstetrics and gynecology.

Lack of influence of dyspareunia on the beneficial effect of intravaginal prasterone (dehydroepiandrosterone, DHEA) on sexual dysfunction in postmenopausal women.

C. Labrie, F. Labrie, C. Martel, 2014, The journal of sexual medicine.

Premature menopause increases cardiovascular risk

D. Archer, 2009, Climacteric : the journal of the International Menopause Society.

Low‐Dose Hormone Therapy for Postmenopausal Women

D. Archer, 2003, Clinical obstetrics and gynecology.

Progestogen effects on coronary arteries: the need for definitive clinical trials.

D. Archer, 2001, Menopause.

Maintenance of the efficacy of desvenlafaxine in menopausal vasomotor symptoms: a 1-year randomized controlled trial

D. Archer, J. Pinkerton, C. Guico-Pabia, 2012, Menopause.

The REJOICE trial: a phase 3 randomized, controlled trial evaluating the safety and efficacy of a novel vaginal estradiol soft-gel capsule for symptomatic vulvar and vaginal atrophy

H. Kushner, J. Simon, G. Constantine, 2017, Menopause.

Effect of intravaginal dehydroepiandrosterone (DHEA) on the female sexual function in postmenopausal women: ERC-230 open-label study

L. Derogatis, F. Labrie, C. Martel, 2016, Hormone molecular biology and clinical investigation.

Bazedoxifene/conjugated estrogens (BZA/CE): incidence of uterine bleeding in postmenopausal women.

V. Lewis, D. Archer, B. Carr, 2009, Fertility and sterility.

Estradiol vaginal inserts (4 µg and 10 µg) for treating moderate to severe vulvar and vaginal atrophy: a review of phase 3 safety, efficacy and pharmacokinetic data

J. Simon, G. Constantine, D. Archer, 2018, Current medical research and opinion.

Visual improvements in vaginal mucosa correlate with symptoms of VVA: data from a double-blind, placebo-controlled trial

J. Simon, G. Constantine, R. Kagan, 2017, Menopause.

Serum levels of sex steroids and metabolites following 12 weeks of intravaginal 0.50% DHEA administration

F. Labrie, C. Martel, D. Archer, 2015, The Journal of Steroid Biochemistry and Molecular Biology.

Influence of treatment of vulvovaginal atrophy with intravaginal prasterone on the male partner

F. Labrie, C. Martel, D. Archer, 2015, Climacteric : the journal of the International Menopause Society.

Pooled Analysis of the Effects of Conjugated Estrogens/Bazedoxifene on Vasomotor Symptoms in the Selective Estrogens, Menopause, and Response to Therapy Trials.

B. Komm, E. Freeman, D. Archer, 2016, Journal of women's health.

Double Dosing Levonorgestrel-Based Emergency Contraception for Individuals With Obesity

D. Archer, J. Jensen, J. Hennebold, 2022, Obstetrics and gynecology.

Effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate on endometrial bleeding.

D. Schneider, V. Lewis, D. Archer, 2001, Fertility and sterility.

Effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate on endometrial bleeding.

D. Schneider, V. Lewis, D. Archer, 2001, Fertility and sterility.

Morbid obesity: potential effects of hormonal contraception.

Kurt M Hong, A. Burke, D. Archer, 2018, Contraception.

Tissue Response to Bioerodible, Subcutaneous Drug Implants: A Possible Determinant of Drug Absorption Kinetics

D. Archer, S. Harman, W. Wilborn, 1993, Pharmaceutical Research.

Elagolix reduced dyspareunia and improved health-related quality of life in premenopausal women with endometriosis-associated pain

P. Peloso, H. Taylor, A. Soliman, 2018, Journal of Endometriosis and Pelvic Pain Disorders.

Efficacy and safety of low, standard, and high dosages of an estradiol transdermal system (Esclim) compared with placebo on vasomotor symptoms in highly symptomatic menopausal patients. The Esclim Study Group.

J. Gallagher, D. Archer, W. Utian, 1999, American journal of obstetrics and gynecology.

Efficacy and safety of low, standard, and high dosages of an estradiol transdermal system (Esclim) compared with placebo on vasomotor symptoms in highly symptomatic menopausal patients

J. Gallagher, D. Archer, W. Utian, 1999 .

Reproductive history and postmenopausal rheumatoid arthritis among women 60 years or older: Third National Health and Nutrition Examination Survey

H. Beydoun, D. Archer, Malikah McNeal, 2013, Menopause.

Chlorpromazine-induced changes in serum prolactin in women with oligomenorrhea, amenorrhea, and pituitary adenoma.

J. Maroon, D. Archer, J. Josimovich, 1977, Fertility and sterility.

Percutaneous 17&bgr;-estradiol gel for the treatment of vasomotor symptoms in postmenopausal women

D. Archer, 2003, Menopause.

A 1-year prospective, open-label, single-arm, multicenter, phase 3 trial of the contraceptive efficacy and safety of the oral progestin-only pill drospirenone 4 mg using a 24/4-day regimen☆☆☆

K. Barnhart, A. Burke, D. Archer, 2020, Contraception: X.

Is bleeding a predictor of endometrial hyperplasia in postmenopausal women receiving hormone replacement therapy? Menopause Study Group (United States, Italy, Netherlands, Switzerland, Belgium, Germany, and Finland.

D. Archer, J. Pickar, 1997, American journal of obstetrics and gynecology.

An expert review and commentary on the efficacy and safety of tranexamic acid for the treatment of heavy menstrual bleeding

I. Fraser, D. Archer, 2013 .

Review of menopausal hormone therapy with estradiol and progesterone versus other estrogens and progestins

J. Simon, D. Archer, S. Graham, 2022, Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology.

Effect of desvenlafaxine on mood and climacteric symptoms in menopausal women with moderate to severe vasomotor symptoms

D. Archer, W. Bao, J. Pickar, 2012, Climacteric : the journal of the International Menopause Society.

Levonorgestrel effects on serum androgens, sex hormone-binding globulin levels, hair shaft diameter, and sexual function.

D. Archer, F. Stanczyk, S. Ballagh, 2010, Fertility and sterility.

Studies on the in vitro spermicidal activity of synthetic magainins.

D. Archer, N. Alexander, J. E. Gretz, 1991 .

Effect of tibolone and its metabolites on vascular endothelial growth factor isoforms 121 and 165 and thrombospondin-1 mRNA in Ishikawa cells

D. Archer, M. Mahony, S. Mirkin, 2004, Menopause.

The effect of progestins on vascular endothelial growth factor, oestrogen receptor and progesterone receptor immunoreactivity and endothelial cell density in human endometrium.

D. Charnock-Jones, Stephen K. Smith, A. Sharkey, 2000, Human reproduction.

Endometrial bleeding in postmenopausal women: with and without hormone therapy

D. Archer, 2011, Menopause.

Bazedoxifene effects on the reproductive tract in postmenopausal women at risk for osteoporosis

A. Chines, G. Constantine, D. Archer, 2009, Menopause.

Changes in concentrations of cervicovaginal immune mediators across the menstrual cycle: a systematic review and meta-analysis of individual patient data

Hugo A. Wefer, Melis N. Anahtar, R. J. Hayes, 2020, BMC Medicine.

Galactorrhea, Amenorrhea, Hyperprolactinemia, and an Empty Sella

J. Maroon, D. Archer, P. Dubois, 1978, Obstetrics and gynecology.

A pilot study: estradiol/progesterone effect on cervico-vaginal cytokines in premenopause and postmenopause

D. Archer, S. Mirkin, I. Sriprasert, 2020, Climacteric : the journal of the International Menopause Society.

Impact on hepatic estrogen-sensitive proteins by a 1-year contraceptive vaginal ring delivering Nestorone® and ethinyl estradiol.

D. Archer, R. Sitruk-Ware, J. Conard, 2016, Contraception.

The effect of the duration of progestin use on the occurrence of endometrial cancer in postmenopausal women

D. Archer, 2001, Menopause.

RETRACTED: Doxycycline alters the expression of matrix metalloproteases in the endometrial cells exposed to ovarian steroids and pro-inflammatory cytokine.

Rongxiu Li, D. Archer, N. Chegini, 2007, Journal of reproductive immunology.

Comparison of intravaginal 6.5mg (0.50%) prasterone, 0.3mg conjugated estrogens and 10μg estradiol on symptoms of vulvovaginal atrophy

F. Labrie, C. Martel, D. Archer, 2017, The Journal of Steroid Biochemistry and Molecular Biology.

Combined data of intravaginal prasterone against vulvovaginal atrophy of menopause

F. Labrie, C. Martel, D. Archer, 2017, Menopause.

Serum steroid levels during 12-week intravaginal dehydroepiandrosterone administration

C. Labrie, R. Bérubé, F. Labrie, 2009, Menopause.

A randomized, multicenter, double-blind study to evaluate the safety and efficacy of estradiol vaginal cream 0.003% in postmenopausal women with dyspareunia as the most bothersome symptom

D. Archer, James H. Liu, Yuhua Lin, 2017, Menopause.

Evaluation of endometrial progesterone receptor expression after 12 weeks of exposure to a low-dose vaginal estradiol insert

B. Komm, Patricia D. Castro, J. Simon, 2021, Menopause.

Continuous combined hormone replacement therapy and endometrial hyperplasia

D. Archer, 2002, BMJ : British Medical Journal.

Postmenopausal uterine bleeding profiles with two forms of continuous combined hormone replacement therapy

G. Bachmann, D. Archer, M. Davidson, 2002, Menopause.

Progestogens: effects on clinical and biochemical parameters in postmenopausal women.

D. Archer, 2005, Menopause.

Population pharmacokinetic/pharmacodynamic evaluation of low-dose drospirenone with 17&bgr;-estradiol in postmenopausal women with moderate to severe vasomotor symptoms

C. Gerlinger, D. Archer, T. Schmelter, 2014, Menopause.

TX-004HR clinically improves symptoms of vulvar and vaginal atrophy in postmenopausal women

J. Simon, G. Constantine, R. Kagan, 2019, Climacteric : the journal of the International Menopause Society.

Effective Treatment of Vaginal Atrophy With an Ultra–Low-Dose Estradiol Vaginal Tablet

R. Gut, J. Simon, D. Archer, 2008, Obstetrics and gynecology.

The gynecologic effects of lasofoxifene, an estrogen agonist/antagonist, in postmenopausal women.

D. Archer, 2011, Menopause.

A vaginal estradiol softgel capsule, TX-004HR, has negligible to very low systemic absorption of estradiol: Efficacy and pharmacokinetic data review.

J. Simon, G. Constantine, D. Archer, 2017, Maturitas.

Uterine bleeding in postmenopausal women on continuous therapy with estradiol and norethindrone acetate. Endometrium Study Group.

D. Archer, J. Arce, M. Dorin, 1999, Obstetrics and gynecology.

Amenorrhea frequency with continuous combined hormone replacement therapy: a retrospective analysis. Menopause Study Group.

D. Archer, J. Pickar, F. Bottiglioni, 1998, Climacteric : the journal of the International Menopause Society.

Elagolix for Heavy Menstrual Bleeding in Women with Uterine Fibroids.

K. Barnhart, E. Puscheck, N. Watts, 2020, The New England journal of medicine.

Elagolix suppresses ovulation in a dose-dependent manner: Results from a 3-month, randomized study in ovulatory women.

D. Archer, K. Chwalisz, Y. Chiu, 2020, The Journal of clinical endocrinology and metabolism.

Elagolix for the management of heavy menstrual bleeding associated with uterine fibroids: results from a phase 2a proof-of-concept study.

A. Soliman, D. Archer, K. Chwalisz, 2017, Fertility and sterility.

A simple inexpensive screening test for endometrial abnormalities in asymptomatic women using tamoxifen.

D. Archer, 2010, Menopause.

Effects of doxycycline on serum and endometrial levels of MMP-2, MMP-9 and TIMP-1 in women using a levonorgestrel-releasing subcutaneous implant.

D. Archer, Shumei Zhao, C. Choksuchat, 2009, Contraception.

Effect of intravaginal dehydroepiandrosterone (Prasterone) on libido and sexual dysfunction in postmenopausal women

C. Labrie, F. Labrie, C. Martel, 2009, Menopause.

Doxycycline alters the expression of inflammatory and immune-related cytokines and chemokines in human endometrial cells: implication in irregular uterine bleeding.

Q. Pan, I. Zineh, R. Williams, 2006, Human reproduction.

The influence of pentoxifylline (Trental) on the antifertility effect of intrauterine devices in rats.

D. Archer, W. Gibbons, J. Ramey, 1994, Fertility and sterility.

A randomized, controlled trial of a low-dose contraceptive containing 20 μg of ethinyl estradiol and 100 μg of levonorgestrel for acne treatment

D. Thiboutot, D. Archer, A. Lemay, 2001 .

Ovarian activity in obese and nonobese women treated with three transdermal contraceptive patches delivering three different doses of ethinyl estradiol and levonorgestrel.

D. Mishell, D. Archer, F. Stanczyk, 2013, Contraception.

Vascular dysfunction as a cause of endometrial bleeding

D. Archer, 2012, Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology.

A phase I study of Femcap used with and without spermicide. Postcoital testing.

C. Mauck, D. Archer, J. Baker, 1997, Contraception.

Lea's Shield: a phase I postcoital study of a new contraceptive barrier device.

C. Mauck, D. Archer, F. Anderson, 1995, Contraception.

Drospirenone-only oral contraceptive: results from a multicenter noncomparative trial of efficacy, safety and tolerability.

D. Archer, D. Drouin, H. Ahrendt, 2015, Contraception.

Original research article Drospirenone-only oral contraceptive: results from a multicenter noncomparative trial of efficacy, safety and tolerability ☆,☆☆

D. Archer, D. Drouin, H. Ahrendt, 2015 .

The effect of one injection of Depo-Provera on the human vaginal epithelium and cervical ectopy.

C. Morrison, R. Veazey, C. Mauck, 1999, Contraception.

Re: effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin.

T. Bush, D. Archer, L. Nachtigall, 2000, Journal of the National Cancer Institute.

Reduction of Heavy Menstrual Bleeding in Women Not Designated as Responders to Elagolix Plus Add Back Therapy for Uterine Fibroids

K. Barnhart, A. Al-Hendy, D. Archer, 2021, Journal of women's health.

Efficacy and safety of elagolix with add-back therapy in women with uterine fibroids and coexisting adenomyosis

K. Barnhart, D. Archer, E. Stewart, 2021, F&S reports.

Elagolix Treatment for Up to 12 Months in Women With Heavy Menstrual Bleeding and Uterine Leiomyomas

K. Barnhart, N. Watts, A. Al-Hendy, 2020, Obstetrics and gynecology.

Elagolix Alone or With Add-Back Therapy in Women With Heavy Menstrual Bleeding and Uterine Leiomyomas: A Randomized Controlled Trial.

N. Watts, A. Soliman, M. Diamond, 2018, Obstetrics and gynecology.

Tolerability and safety of the estetrol/drospirenone combined oral contraceptive: Pooled analysis of two multicenter, open-label phase 3 trials.

J. Foidart, T. Piltonen, S. Weyers, 2022, Contraception.

A comparison of techniques to assess cervicovaginal irritation and evaluation of the variability between two observers.

C. Mauck, M. Callahan, D. Archer, 2004, Contraception.

Heavy menstrual bleeding diagnosis and medical management

D. Archer, I. Sriprasert, T. Kimble, 2017, Contraception and Reproductive Medicine.

Extended regimen of a levonorgestrel/ethinyl estradiol transdermal delivery system: Predicted serum hormone levels using a population pharmacokinetic model

Jason R. Pirone, D. Archer, F. Stanczyk, 2022, PloS one.

Evaluation of a continuous regimen of levonorgestrel/ethinyl estradiol: phase 3 study results.

G. Constantine, D. Archer, J. Jensen, 2006, Contraception.

Postmenopausal hormone therapy: an Endocrine Society scientific statement.

J. Manson, G. Colditz, N. Boyd, 2010, The Journal of clinical endocrinology and metabolism.

Initial and steady-state pharmacokinetics of a vaginally administered formulation of progesterone.

D. Archer, W. Snipes, R. Foldesy, 1995, American journal of obstetrics and gynecology.

Contraceptive Efficacy, Acceptability, and Safety of C31G and Nonoxynol-9 Spermicidal Gels: A Randomized Controlled Trial

K. Barnhart, T. Walsh, A. Burke, 2010, Obstetrics and gynecology.

Pharmacokinetics and adhesion of the Agile transdermal contraceptive patch (AG200-15) during daily exposure to external conditions of heat, humidity and exercise.

D. Archer, F. Stanczyk, A. Rubin, 2013, Contraception.

Human vaginal pH and microbiota: an update

D. Archer, S. Mirkin, Keshav Godha, 2018, Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology.

Vaginal pH: a simple assessment highly correlated with vaginal morphology and symptoms in postmenopausal women

D. Archer, S. Mirkin, Keshav Godha, 2018, Menopause.

A randomized comparison of the effects on vaginal and cervical epithelium of a placebo vaginal ring with non-use of a ring.

I. Fraser, P. Soutter, D. Archer, 2000, Contraception.

Postmenopausal skin and estrogen

D. Archer, 2012, Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology.

Etiology of Recurrent Pregnancy Losses and Outcome of Subsequent Pregnancies

D. Archer, J. Harger, S. Marchese, 1983, Obstetrics and gynecology.

Single and multiple exposure tolerance study of polystyrene sulfonate gel: a phase I safety and colposcopy study.

D. Weiner, C. Mauck, M. Callahan, 2001, Contraception.

Contraception: New Approaches and Future Perspectives

D. Baird, D. Archer, H. Croxatto, 2001 .

Safety and efficacy of Implanon, a single-rod implantable contraceptive containing etonogestrel.

D. Mishell, D. Archer, Jüergen Schmidt, 2005, Contraception.

Original research article Safety and efficacy of Implanonk, a single-rod implantable contraceptive containing etonogestrel

D. Mishell, D. Archer, Jüergen Schmidt, 2005 .

Effects of ethinyl estradiol and ibuprofen compared to placebo on endometrial bleeding, cervical mucus and the postcoital test in levonorgestrel subcutaneous implant users.

D. Archer, V. Cullins, C. Philput, 2008, Contraception.

Management of irregular uterine bleeding and spotting associated with Norplant.

D. Archer, C. Philput, M. E. Weber, 1996, Human reproduction.

Tailoring combination oral contraceptives to the individual woman.

D. Archer, Ignacio Lete Lasa, 2011, Journal of women's health.

Oral contraceptive efficacy and antibiotic interaction: a myth debunked.

D. Archer, J. Archer, 2002, Journal of the American Academy of Dermatology.

Ethinyl estradiol and levonorgestrel in a transdermal contraceptive delivery system

D. Archer, F. Stanczyk, I. Sriprasert, 2015, Expert opinion on pharmacotherapy.

Ethinyl estradiol and levonorgestrel pharmacokinetics with a low-dose transdermal contraceptive delivery system, AG200-15: a randomized controlled trial.

D. Archer, F. Stanczyk, A. Rubin, 2012, Contraception.

Original research article Ethinyl estradiol and levonorgestrel pharmacokinetics with a low-dose transdermal contraceptive delivery system, AG200-15: a randomized controlled trial ☆

D. Archer, F. Stanczyk, A. Rubin, 2012 .

Medroxyprogesterone acetate and estradiol cypionate injectable suspension (Cyclofem) monthly contraceptive injection: steady-state pharmacokinetics.

A. Thurman, J. Schwartz, D. Archer, 2013, Contraception.

Continuation rates of two different-sized copper intrauterine devices among nulliparous women: Interim 12-month results of a single-blind, randomised, multicentre trial

B. Kaneshiro, A. Burke, D. Archer, 2022, EClinicalMedicine.

Long-Term Outcomes of Elagolix in Women With Endometriosis: Results From Two Extension Studies.

L. Giudice, S. Agarwal, P. Peloso, 2018, Obstetrics and gynecology.

Ortho Evra/Evra versus oral contraceptives: follicular development and ovulation in normal cycles and after an intentional dosing error.

R. Pierson, A. Fisher, D. Archer, 2003, Fertility and sterility.

New contraceptive patch wearability assessed by investigators and participants in a randomized phase 3 study.

D. Mishell, D. Archer, C. Westhoff, 2015, Contraception.

Original research article New contraceptive patch wearability assessed by investigators and participants in a randomized phase 3 study

D. Mishell, D. Archer, C. Westhoff, 2015 .

Transdermal Contraceptive Delivery Systems

D. Archer, I. Sriprasert, 2020, The Handbook of Contraception.

Prolactin-secreting pituitary adenomas: serum and tissue prolactin levels with ultrastructural correlation.

J. Maroon, D. Archer, L. Hough, 1980, American journal of obstetrics and gynecology.

The Plasminogen Activator System, Glucocorticoid, and Mineralocorticoid Receptors in the Primate Endometrium During Artificial Menstrual Cycles

D. Archer, N. Chandra, E. Demirel, 2021, Reproductive Sciences.

An evaluation of the amount of nonoxynol-9 remaining in the vagina up to 4 h after insertion of a vaginal contraceptive film (VCF) containing 70 mg nonoxynol-9.

C. Mauck, D. Archer, S. Allen, 1997, Contraception.

Drospirenone Effects on the Plasminogen Activator System in Immortalized Human Endometrial Endothelial Cells

D. Archer, T. Jacot, R. Sabouni, 2021, Reproductive Sciences.

Medical Management of Menorrhagia in Pre- and Perimenopausal Women

D. Archer, 1997 .

Effects of levonorgestrel, medroxyprogesterone acetate, norethindrone, progesterone, and 17beta-estradiol on thrombospondin-1 mRNA in Ishikawa cells.

D. Archer, S. Mirkin, 2004, Fertility and sterility.

The role of androgens in the treatment of genitourinary syndrome of menopause (GSM): International Society for the Study of Women's Sexual Health (ISSWSH) expert consensus panel review

I. Goldstein, A. Traish, G. Bachmann, 2018, Menopause.

Vaginal atrophy and disease susceptibility: the role of leukocytes.

D. Archer, 2015, Menopause.

Clinical Challenges of Perimenopause: Consensus Opinion of The North American Menopause Society

N. Avis, N. Santoro, D. Archer, 2000, Menopause.

Vaginal cytokines do not differ between postmenopausal women with and without symptoms of vulvovaginal irritation

N. Bersinger, A. Thurman, Z. Kollmann, 2014, Menopause.

FemCap with removal strap: ease of removal, safety and acceptability.

D. Weiner, C. Mauck, M. Callahan, 2006, Contraception.

Ultrastructural changes of the human corpus luteum of pregnancy induced by prostaglandin E2 in vitro.

D. Archer, H. Salazar, 1974, European journal of obstetrics, gynecology, and reproductive biology.

Management of the Menopause.

D. Archer, T. Detre, T. Hayashi, 1978, Annals of internal medicine.

Effect of Intravaginal Prasterone on Sexual Dysfunction in Postmenopausal Women with Vulvovaginal Atrophy.

L. Derogatis, F. Labrie, C. Martel, 2015, The journal of sexual medicine.

Lack of effect of intravaginal dehydroepiandrosterone (DHEA, prasterone) on the endometrium in postmenopausal women

F. Labrie, C. Martel, D. Archer, 2015, Menopause.

Prasterone has parallel beneficial effects on the main symptoms of vulvovaginal atrophy: 52-week open-label study.

C. Labrie, F. Labrie, C. Martel, 2015, Maturitas.

Endometrial safety of ospemifene: results of the phase 2/3 clinical development program

G. Constantine, D. Archer, S. Goldstein, 2015, Menopause.

Treatment of pain at sexual activity (dyspareunia) with intravaginal dehydroepiandrosterone (prasterone)

C. Labrie, F. Labrie, C. Martel, 2015, Menopause.

Efficacy and safety of ospemifene in postmenopausal women with moderate-to-severe vaginal dryness: a phase 3, randomized, double-blind, placebo-controlled, multicenter trial

S. Sussman, J. Simon, D. Archer, 2019, Menopause.

Estrogen and progestogen use in peri- and postmenopausal women: March 2007 position statement of The North American Menopause Society

J. Manson, V. Henderson, R. Karas, 2007, Menopause.

The effects of a low-dose monophasic preparation of levonorgestrel and ethinyl estradiol on coagulation and other hemostatic factors.

E. Mammen, D. Archer, G. Grubb, 1999, American journal of obstetrics and gynecology.

Lea's Shield: a study of the safety and efficacy of a new vaginal barrier contraceptive used with and without spermicide.

C. Mauck, D. Archer, S. Allen, 1996, Contraception.

Symptomatic Pituitary Tumor Enlargement After Induced Pregnancy

P. Nelson, J. Maroon, D. Archer, 1978 .

Symptomatic pituitary tumor enlargement after induced pregnancy. Case report.

P. Nelson, J. Maroon, D. Archer, 1978, Journal of neurosurgery.

Bromocriptine treatment of women with suspected pituitary prolactin-secreting microadenomas.

D. Herbert, D. Archer, J. Harger, 1982, American journal of obstetrics and gynecology.

Amenorrhea and galactorrhea: Results of therapy with 2-Brom-α-ergocryptine (CB-154)

D. Archer, S. J. Lloyd, J. Josimovich, 1975 .

Efficacy and safety of a low-dose monophasic combination oral contraceptive containing 100 microg levonorgestrel and 20 microg ethinyl estradiol (Alesse). North american Levonorgestrel Study Group (NALSG).

D. Archer, R. Maheux, A. Delconte, 1999, American Journal of Obstetrics and Gynecology.

Role of progestogen in hormone therapy for postmenopausal women: position statement of The North American Menopause Society.

D. Archer, F. Stanczyk, 2003, Menopause.

Effect of 17β-estradiol, progesterone, synthetic progestins, tibolone, and tibolone metabolites on vascular endothelial growth factor mRNA in breast cancer cells

D. Archer, S. Mirkin, B. C. Wong, 2005 .

THE FALLACY OF THE POSTPILL AMENORRHEA SYNDROME

D. Archer, R. Thomas, 1981, Clinical obstetrics and gynecology.

Fertility following Steroidal Oral Contraception and Diethylstilbestrol Exposure

D. Archer, 1987 .

Pharmacokinetics of subcutaneous depot medroxyprogesterone acetate injected in the upper arm.

D. Weiner, D. Archer, L. Dorflinger, 2012, Contraception.

Response of serum prolactin to exogenous stimulation.

D. Archer, J. Josimovich, 1975, Fertility and sterility.

Hormone Replacement Therapy: Effect of Progestin Dose and Time Since Menopause on Endometrial Bleeding

D. Archer, J. Pickar, JAMES H. PICKAR, 2000, Obstetrics and gynecology.

Effects of tibolone and its metabolites on Angiopoietin-1, Tie-2 and tumor necrosis factor-α mRNA in Ishikawa cells

D. Archer, S. Mirkin, 2007 .

Endometriosis-associated pelvic pain: evidence for an association between the stage of disease and a history of chronic pelvic pain.

D. Archer, D. Guzick, D. Stovall, 1997, Fertility and sterility.

The past, the present and the future o oestrogen and progestogen therapy for cardiovascular disease in postmenopausal women

D. Archer, 2000 .

Uterine bleeding with hormone therapies in menopausal women: a systematic review

R. Kagan, D. Archer, S. Mirkin, 2020, Climacteric : the journal of the International Menopause Society.

Neurophysin in women during oxytocin-related events.

D. Archer, A. G. Robinson, L. F. Tolstoi, 1973, The Journal of clinical endocrinology and metabolism.

Endometrial safety and bleeding profile of a 17β-estradiol/progesterone oral softgel capsule (TX-001HR)∗

D. Archer, S. Mirkin, J. Pickar, 2020, Menopause.

A 17β-Estradiol-Progesterone Oral Capsule for Vasomotor Symptoms in Postmenopausal Women: A Randomized Controlled Trial.

G. Constantine, R. Kagan, D. Archer, 2018, Obstetrics and gynecology.

Safety and benefit considerations for menopausal hormone therapy

H. Taylor, R. Kagan, D. Archer, 2017, Expert opinion on drug safety.

Norethindrone Acetate and Estradiol‐Induced Endometrial Hyperplasia

R. Kurman, D. Archer, J. Felix, 2000, Obstetrics and gynecology.

Menopausal hormone therapy for primary prevention: why the USPSTF is wrong

R. Langer, P. Sarrel, A. Pines, 2017, Menopause.

Menopausal hormone therapy for primary prevention: why the USPSTF is wrong

R. Langer, P. Sarrel, A. Pines, 2017, Climacteric : the journal of the International Menopause Society.

Estrogen and progestogen use in postmenopausal women: July 2008 position statement of The North American Menopause Society

J. Manson, V. Henderson, R. Karas, 2008, Menopause.

Estradiol gel: review of the pharmacology, pharmacokinetics, efficacy, and safety in menopausal women

D. Archer, J. Brouwers, M. Naunton, 2006, Menopause.

The effects of the etonogestrel 0.12mg/ethinyl estradiol 0.015mg vaginal ring (NuvaRing®) on inflammatory biomarkers

R. Fichorova, A. Thurman, D. Archer, 2017 .

Single and multiple exposure tolerance study of cellulose sulfate gel: a Phase I safety and colposcopy study.

D. Weiner, C. Mauck, M. Callahan, 2001, Contraception.

Bleeding Patterns of Oral Contraceptives with a Cyclic Dosing Regimen: An Overview

J. Foidart, D. Archer, D. Mansour, 2022, Journal of clinical medicine.

Efficacy and safety of a low-dose monophasic combination oral contraceptive containing 100 μg levonorgestrel and 20 μg ethinyl estradiol (Alesse®)

D. Archer, R. Maheux, A. Delconte, 1999 .

A new low-dose monophasic combination oral contraceptive (Alesse™) with levonorgestrel 100 μg and ethinyl estradiol 20 μg

D. Archer, R. Maheux, A. Delconte, 1997 .

A new low-dose monophasic combination oral contraceptive (Alesse) with levonorgestrel 100 micrograms and ethinyl estradiol 20 micrograms. North American Levonorgestrel Study Group (NALSG).

D. Archer, R. Maheux, A. Delconte, 1997, Contraception.

A phase I comparative study of contraceptive vaginal films containing benzalkonium chloride and nonoxynol-9. Postcoital testing and colposcopy.

C. Mauck, D. Archer, J. Baker, 1997, Contraception.

Contraceptive efficacy, safety and acceptability of SILCS, a novel single-sized diaphragm used with contraceptive gel

K. Barnhart, D. Weiner, C. Mauck, 2012 .

Contraceptive Efficacy of a Novel Spermicidal Microbicide Used With a Diaphragm: A Randomized Controlled Trial

K. Barnhart, Sutapa Das, T. Walsh, 2007, Obstetrics and gynecology.

Safety of single daily use for one week of C31G HEC gel in women.

D. Archer, S. Ballagh, J. Baker, 2002, Contraception.

Development of a Composite Measure of Product Adherence, Protocol Compliance, and Semen Exposure Using DNA and Protein Biomarkers for Topical HIV Prevention Studies

G. Doncel, A. Thurman, D. Archer, 2014, PloS one.

A phase I comparative postcoital testing study of three concentrations of C31G.

K. Barnhart, R. Bax, C. Mauck, 2004, Contraception.

CONTRACEPTION FOR THE 21st CENTURY.

D. Archer, 2001, Clinical obstetrics and gynecology.

Progesterone Receptor Modulator for Emergency Contraception: A Randomized Controlled Trial

R. Frezieres, D. Archer, W. Schlaff, 2006, Obstetrics and gynecology.

Clinical and metabolic features of desogestrel: a new oral contraceptive preparation.

D. Archer, 1994, American journal of obstetrics and gynecology.

Prescribing of FDA-approved and compounded hormone therapy differs by specialty

G. Constantine, D. Archer, S. Mirkin, 2016, Menopause.

Desvenlafaxine for the treatment of vasomotor symptoms associated with menopause: a double-blind, randomized, placebo-controlled trial of efficacy and safety.

G. Constantine, D. Archer, J. Pickar, 2009, American journal of obstetrics and gynecology.

Segesterone Acetate Serum Levels with a Regression Model of Continuous Use of the Segesterone Acetate/Ethinyl Estradiol Contraceptive Vaginal System.

J. Simon, D. Archer, S. Mirkin, 2021, Contraception.

A double-blind, randomly assigned, placebo-controlled study of desvenlafaxine efficacy and safety for the treatment of vasomotor symptoms associated with menopause.

G. Constantine, D. Archer, J. Pickar, 2009, American journal of obstetrics and gynecology.

Contraceptive Efficacy, Safety, Fit, and Acceptability of a Single-Size Diaphragm Developed With End-User Input

K. Barnhart, D. Weiner, C. Mauck, 2015, Obstetrics and gynecology.

Efficacy and safety of a new 24-day oral contraceptive regimen of norethindrone acetate 1 mg/ethinyl estradiol 20 micro g (Loestrin 24 Fe).

S. Nakajima, D. Archer, H. Ellman, 2007, Contraception.

A randomized, controlled trial of a low-dose contraceptive containing 20 microg of ethinyl estradiol and 100 microg of levonorgestrel for acne treatment.

D. Thiboutot, D. Archer, A. Lemay, 2001, Fertility and sterility.

Efficacy and safety of a low-dose monophasic combination oral contraceptive containing 100 micrograms levonorgestrel and 20 micrograms ethinyl estradiol (Alesse).

D. Archer, R. Maheux, A. Delconte, 1999 .

Ovarian activity and safety of a novel levonorgestrel/ethinyl estradiol continuous oral contraceptive regimen.

D. Archer, G. Grubb, S. Ballagh, 2009, Contraception.

Norethindrone Acetate 1.0 Milligram and Ethinyl Estradiol 10 Micrograms as an Ultra Low-Dose Oral Contraceptive

Steven T. Nakajima, S. Nakajima, R. Gilbert, 2013, Obstetrics and gynecology.

Mifepristone: a potential contraceptive.

D. Archer, O. Heikinheimo, 1996, Clinical obstetrics and gynecology.

Dose-finding study of a 90-day contraceptive vaginal ring releasing estradiol and segesterone acetate.

K. Barnhart, D. Archer, Melissa J. Chen, 2020, Contraception.

Safety and tolerability of a new low-dose contraceptive patch in obese and nonobese women.

D. Mishell, D. Archer, A. Kaunitz, 2015, American journal of obstetrics and gynecology.

Evaluation of ovulation and safety outcomes in a multi-center randomized trial of three 84-day ulipristal acetate regimens.

K. Barnhart, M. Gilliam, P. Darney, 2022, Contraception.

Contraceptive efficacy, pharmacokinetics, and safety of Annuelle biodegradable norethindrone pellet implants.

D. Archer, E. Raymond, J. Baker, 1996, Fertility and sterility.

Reversible contraception for the woman over 35 years of age

D. Archer, 1992, Current opinion in obstetrics & gynecology.

New contraceptive options.

D. Archer, 2001, Clinical obstetrics and gynecology.

Effects of levonorgestrel, medroxyprogesterone acetate, norethindrone, and 17beta-estradiol on vascular endothelial growth factor isomers 121 and 165 in Ishikawa cells.

D. Archer, S. Mirkin, Francisco J Navarro, 2004, Fertility and sterility.

The effect of etonogestrel on VEGF, oestrogen and progesterone receptor immunoreactivity and endothelial cell number in human endometrium.

D. Charnock-Jones, S. Smith, D. Archer, 1999, Human reproduction.

Elagolix in the treatment of endometriosis: impact beyond pain symptoms

S. Agarwal, H. Taylor, A. Soliman, 2020, Therapeutic advances in reproductive health.

A Randomized, Multicenter, Double-Blind, Study to Evaluate the Safety and Efficacy of Estradiol Vaginal Cream 0.003% in Postmenopausal Women with Vaginal Dryness as the Most Bothersome Symptom

James H. Liu, D. Archer, T. Kimble, 2017, Journal of women's health.

Management of pelvic endometriosis with low-dose danazol.

J. Rock, D. Archer, J. Harger, 1981, Fertility and sterility.

Dehydroepiandrosterone intra vaginal administration for the management of postmenopausal vulvovaginal atrophy

D. Archer, 2015, The Journal of Steroid Biochemistry and Molecular Biology.

Decreased efficacy of twice-weekly intravaginal dehydroepiandrosterone on vulvovaginal atrophy

C. Labrie, F. Labrie, C. Martel, 2015, Climacteric : the journal of the International Menopause Society.

Transdermal estradiol gel for the treatment of symptomatic postmenopausal women

D. Archer, M. Warren, J. Pickar, 2012, Menopause.

A core outcome set for vasomotor symptoms associated with menopause: the COMMA (Core Outcomes in Menopause) global initiative

L. Kiesel, S. Iliodromiti, M. Hickey, 2021, Menopause.

High internal consistency and efficacy of intravaginal DHEA for vaginal atrophy

C. Labrie, F. Labrie, C. Martel, 2010, Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology.

Consistency of Effect with a Low-Dose, Estradiol Vaginal Capsule (TX-004HR): Evaluating Improvement in Vaginal Physiology and Moderate-to-Severe Dyspareunia in Subgroups of Postmenopausal Women

G. Constantine, D. Archer, C. Bouchard, 2017, Journal of women's health.

TX-004HR vaginal estradiol has negligible to very low systemic absorption of estradiol

H. Kushner, J. Simon, G. Constantine, 2017, Menopause.

Gynecologic Safety of Conjugated Estrogens Plus Bazedoxifene: Pooled Analysis of Five Phase 3 Trials.

B. Komm, R. Kagan, D. Archer, 2016, Journal of women's health.

Ospemifene: less venous thrombosis than other selective estrogen receptor modulators in postmenopausal women with vulvo vaginal atrophy.

D. Archer, 2020, Menopause.

Updated practical recommendations for hormone replacement therapy in the peri- and postmenopause

H. Burger, N. Panay, D. Archer, 2008, Climacteric : the journal of the International Menopause Society.

A randomized comparison of continuous combined transdermal delivery of estradiol-norethindrone acetate and estradiol alone for menopause. CombiPatch Study Group.

D. Archer, D. Tipping, M. Dain, 1999, Obstetrics and gynecology.

Ospemifene's effect on vasomotor symptoms: a post hoc analysis of phase 2 and 3 clinical data

G. Constantine, D. Archer, Wei Jiang, 2016, Menopause.

Endometrial histology during use of a low-dose estrogen-desogestrel oral contraceptive with a reduced hormone-free interval.

D. Archer, 1999, Contraception.

Acute Changes in Serum Estradiol Concentrations Do Not Elicit Changes in Serum Osteocalcin Concentrations

D. Archer, R. Scott, V. Karande, 1990 .

Suppression of luteal phase, but not midcycle, prolactin levels by chronic follicular phase opiate antagonism.

D. Archer, R. Brzyski, A. Viniegra, 1997, Fertility and sterility.

Continuous dosing of a novel contraceptive vaginal ring releasing Nestorone® and estradiol: pharmacokinetics from a dose-finding study.

K. Barnhart, A. Burke, D. Archer, 2018, Contraception.

Journal of Steroid Biochemistry and Molecular Biology Comparison of intravaginal 0.5% prasterone, 0.3 mg conjugated estrogens and 10 μg estradiol on estrogen-related symptoms of vulvovaginal atrophy

F. Labrie, D. Archer, M. Montesino, 2017 .

Endometrial expression of epithelial neutrophil-activating peptide-78 during the menstrual cycle or in progestin-only contraceptive users with breakthrough bleeding and the influence of doxycycline therapy.

Q. Pan, D. Archer, N. Chegini, 2007, Human reproduction.

Low-Dose Levonorgestrel and Ethinyl Estradiol Patch and Pill: A Randomized Controlled Trial

D. Mishell, D. Archer, C. Westhoff, 2014, Obstetrics and gynecology.

Desvenlafaxine: a therapeutic option for treatment of menopausal hot flashes.

D. Archer, 2010, Maturitas.

Efficacy of the 1-year (13-cycle) segesterone acetate and ethinylestradiol contraceptive vaginal system: results of two multicentre, open-label, single-arm, phase 3 trials

D. Apter, P. Darney, D. Archer, 2019, The Lancet. Global health.

Self-reported and verified compliance in a phase 3 clinical trial of a novel low-dose contraceptive patch and pill.

D. Mishell, D. Archer, C. Westhoff, 2015, Contraception.

TSPY4 is a novel sperm-specific biomarker of semen exposure in human cervicovaginal fluids; potential use in HIV prevention and contraception studies.

G. Doncel, C. Mauck, I. Zalenskaya, 2013, Contraception.

Assessment of the vaginal residence time of biomarkers of semen exposure.

G. Doncel, C. Mauck, A. Thurman, 2016, Contraception.

Bazedoxifene, a selective estrogen receptor modulator: effects on the endometrium, ovaries, and breast from a randomized controlled trial in osteoporotic postmenopausal women

A. Chines, G. Constantine, D. Archer, 2009, Menopause.

Estetrol-Drospirenone Combination Oral Contraceptive: North American Phase 3 Efficacy and Safety Results.

J. Foidart, D. Archer, Melissa J. Chen, 2021, Contraception.

The Effect of Levonorgestrel on Fibrinolytic Factors in Human Endometrial Endothelial Cells

D. Archer, Joelle E Taylor, T. Pakrashi, 2016, Reproductive Sciences.

Hormone therapy and endometrial angiogenesis

D. Archer, S. Mirkin, Francisco J Navarro, 2003, Climacteric : the journal of the International Menopause Society.

Hormone therapy and endometrial

D. Archer, Francisco J Navarro, 2003 .

A combined, bioidentical, oral, 17β-estradiol and progesterone capsule for the treatment of moderate to severe vasomotor symptoms due to menopause

D. Archer, S. Mirkin, B. Bernick, 2019, Expert review of clinical pharmacology.

17β-Estradiol and natural progesterone for menopausal hormone therapy: REPLENISH phase 3 study design of a combination capsule and evidence review.

D. Archer, S. Mirkin, J. Pickar, 2015, Maturitas.

Recent advances help understand and improve the safety of menopausal therapies

B. Komm, D. Archer, S. Mirkin, 2015, Menopause.

Effects of 17β-estradiol, progesterone, synthetic progestins, tibolone, and raloxifene on vascular endothelial growth factor and Thrombospondin-1 messengerRNA in breast cancer cells

D. Archer, S. Mirkin, B. C. Wong, 2006 .

Incidence of endometrial spotting or bleeding during continuous-combined estrogen-progestin therapy in postmenopausal women with and without hypertension

A. LaCroix, H. Beydoun, D. Archer, 2015, Menopause.

Interrelationships of Sex, Physician-Diagnosed Arthritis, Chronic Inflammation, and Physical Functioning in the Third National Health and Nutrition Examination Surveys

A. Zonderman, H. Beydoun, M. Beydoun, 2015, Gerontology & geriatric medicine.

Inability to establish ectopic endometrium in a natural killer cell-deficient murine model. Immunologic, histologic and histochemical assessment.

A. Campbell, D. Archer, K. L. Sharpe-Timms, 1996, The Journal of reproductive medicine.

Comparison of self-reported female condom failure and biomarker-confirmed semen exposure.

K. Barnhart, C. Mauck, R. Frezieres, 2019, Contraception.

67 SAFETY AND TOLERABILITY OF BAZEDOXIFENE/CONJUGATED ESTROGENS IN POSTMENOPAUSAL WOMEN: FINDINGS FROM A 1 -YEAR, RANDOMIZED, PLACEBO- AND ACTIVE-CONTROLLED, PHASE 3 TRIAL

A. Chines, D. Archer, R. Lobo, 2012 .

Practical recommendations for hormone replacement therapy in the peri- and postmenopause

H. Burger, T. Maudelonde, A. Genazzani, 2004, Climacteric : the journal of the International Menopause Society.

Ovarian Response to Exogenous Gonadotropins in Women With Elevated Serum Prolactin

D. Archer, J. Josimovich, 1976, Obstetrics and gynecology.

To the Editor.

F. Labrie, C. Martel, D. Archer, 2016, Menopause.

Pharmacokinetics of a triphasic oral contraceptive containing desogestrel and ethinyl estradiol.

D. Archer, P. Lammers, C. Timmer, 1994, Fertility and sterility.

The role of lactogenic hormones in the pregnant woman and the fetus.

D. Archer, J. Josimovich, 1977, American journal of obstetrics and gynecology.

In Reply.

H. Kushner, J. Simon, G. Constantine, 2017, Menopause.

Endometriosis-Related Pain Reduction During Bleeding and Nonbleeding Days in Women Treated with Elagolix

S. Agarwal, D. Archer, K. Chwalisz, 2021, Journal of Pain Research.

Bone turnover changes in women treated with elagolix or placebo during the elaris EM-I and EM-II trials who did not continue in the extension studies

P. Peloso, N. Watts, D. Archer, 2018, Fertility and Sterility.

Drospirenone-containing hormone therapy for postmenopausal women. Perspective on current data.

D. Archer, 2007, The Journal of reproductive medicine.

The importance of pharmacokinetic studies in drug development.

D. Archer, 2013, Contraception.

Effect of exogenous luteinizing hormone-releasing hormone on hypothalamic pituitary function in women with ovarian failure.

D. Archer, C. Kubik, J. L. Albert, 1987, Fertility and sterility.

Use of Luteinizing Hormone-Releasing Hormone for Ovulation Induction

D. Archer, 1986 .

Effects of clomiphene citrate on episodic luteinizing hormone secretion throughout the menstrual cycle

D. Archer, S. Oehninger, R. Brzyski, 1989, American journal of obstetrics and gynecology.

Endocrinology of the Menstrual Cycle

D. Archer, 1984, Clinical obstetrics and gynecology.

The relationship between serum estradiol-17 beta concentrations and induced pituitary luteinizing hormone surges in postmenopausal women.

D. Archer, R. Scott, V. Karande, 1990, Fertility and sterility.

Ovarian follicular maturation in women. I. Intermittent versus daily administration of human menopausal gonadotropin.

D. Archer, G. A. Zikria, C. Tyndall, 1986, Fertility and sterility.

Ovarian follicular maturation in women. II. Reversal of estrogen inhibited ovarian folliculogenesis by human gonadotropin.

H. Rockette, A. Zeleznik, D. Archer, 1988 .

Evaluation of the acceptability of intravaginal prasterone ovule administration using an applicator

F. Labrie, C. Martel, D. Archer, 2016, Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology.

Postmenopausal hormone therapy: an Endocrine Society scientific statement.

J. Manson, G. Colditz, N. Boyd, 2010, The Journal of clinical endocrinology and metabolism.

Validity of hypothalamic-pituitary testing in hyperprolactinemia: prolactin responses to insulin hypoglycemia and arginine.

D. Archer, J. Harger, E. Moore, 1981, American journal of obstetrics and gynecology.

Serum prolactin in patients with inappropriate lactation.

J. Maroon, D. Archer, J. Josimovich, 1974, American journal of obstetrics and gynecology.

Pituitary gonadotropin response in women with idiopathic hyperprolactinemia.

D. Archer, J. Josimovich, H. Nankin, 1976, Fertility and Sterility.

The efficacy, safety and tolerability of an estrogen-free oral contraceptive drospirenone 4 mg (24/4-day regimen) in obese users.

D. Archer, E. Colli, M. Creinin, 2023, Contraception.

Delivery of therapeutic agents to the target tissue.

D. Archer, 2011, Menopause.

Loss of cerebral regulation during cardiac output variations in focal cerebral ischemia.

T. Keller, B. Tranmer, D. Archer, 1992, Journal of neurosurgery.

Re: Estrogen plus progestin and breast cancer incidence and mortality in the women's health initiative observational study.

S. Shapiro, H. Burger, A. Pines, 2014, Journal of the National Cancer Institute.

Physiology of prolactin.

D. Archer, 1980, Clinical obstetrics and gynecology.

Changes in concentrations of cervicovaginal immune mediators across the menstrual cycle: a systematic review and meta-analysis of individual patient data

Hugo A. Wefer, Melis N. Anahtar, R. J. Hayes, 2022, BMC Medicine.

Therapeutically equivalent pharmacokinetic profile across three application sites for AG200-15, a novel low-estrogen dose contraceptive patch.

D. Archer, F. Stanczyk, A. Rubin, 2013, Contraception.

Assessment of the vaginal residence time of biomarkers of semen exposure.

G. Doncel, C. Mauck, A. Thurman, 2016, Contraception.

Human vaginal pH and microbiota: an update

D. Archer, S. Mirkin, Keshav Godha, 2018, Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology.

Effect of Intravaginal Prasterone on Sexual Dysfunction in Postmenopausal Women with Vulvovaginal Atrophy.

L. Derogatis, F. Labrie, C. Martel, 2015, The journal of sexual medicine.

Pituitary Luteinizing Hormone Secretion

D. Archer, R. Scott, V. Karande, 1990 .

REPRODUCTIVE ENDOCRINOLOGY AND INFERTILITY A double-blind, randomly assigned, placebo-controlled study of desvenlafaxine efficacy and safety for the treatment of vasomotor symptoms associated with menopause

G. Constantine, D. Archer, J. Pickar, 2009 .

A 17β-Estradiol-Progesterone Oral Capsule for Vasomotor Symptoms in Postmenopausal Women: A Randomized Controlled Trial.

G. Constantine, R. Kagan, D. Archer, 2018, Obstetrics and gynecology.

Oral estradiol/micronized progesterone may be associated with lower risk of venous thromboembolism compared with conjugated equine estrogens/medroxyprogesterone acetate in real-world practice.

N. Panay, R. Kagan, D. Archer, 2023, Maturitas.

Biosynthesis of estetrol in human pregnancy: Potential pathways

D. Archer, F. Stanczyk, 2023, Journal of Steroid Biochemistry and Molecular Biology.

Endometrial Safety of Ospemifene and the Ability of Transvaginal Ultrasonography to Detect Small Changes in Endometrial Thickness

J. Simon, G. Constantine, D. Archer, 2014 .